Why Use Adis R&D Insight?
Each file on Dialog has its advantages. Note the major benefits of this file below.
- Content of particular interest to those working in pharmaceutical R&D, licensing and marketing and researchers in healthcare institutions.
- Contains adverse events data.
- Includes the therapeutic classification scheme developed by the European Pharmaceutical Market Research Association (EPhMRA) and also contains World Health Organization (WHO) classification.
- Provides extensive pharmacological and pharmacokinetic information
- One of the best sources for nomenclature—drug names, synonyms.
- Consistently classifies drugs by indication with coordinated indexing of indications with stage of development and target markets
- Provides Adis therapeutic value rating related to specific indications.
- Contains commercial summary and forecast by Lehman Brothers.
Go to the next page.
4-3